Travere Therapeutics has acquired 3 companies.
Travere Therapeutics’ largest acquisition to date was in 2014, when it acquired Manchester Pharmaceuticals for $63M. Travere Therapeutics has acquired in 3 different US states. The Company’s most targeted sectors include life science (100%).
3611 Valley Centre Drive, Suite 300,
San Diego, California
92130
United States,
(888) 969-7879
www.travere.com
| Date | Target |
Value
$mlns |
Transaction Type | Acquirer | Seller |
SRC
Link |
|---|---|---|---|---|---|---|
| 2016-06-20 |
Asklepion - Liquid Formulation Of Ursodeoxycholic Acid · Life Science
, United States Asklepion - Liquid Formulation Of Ursodeoxycholic Acid also known as ursodiol or UDCA, ursodeoxycholic acid is a naturally occurring hydrophilic bile acid derived from cholesterol, which is indicated for the treatment of PBC and currently prescribed only in solid forms. Introducing a liquid formulation of ursodeoxycholic acid would provide healthcare professionals with a dosing alternative for patients who have difficulty swallowing tablets or capsules, and may facilitate increased compliance. |
- | Divestiture |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
